INSMED INC Contract with Customer, Asset, Allowance for Credit Loss
INSMED INC (INSM) had Contract with Customer, Asset, Allowance for Credit Loss of $79.36 million as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Balance Sheet › Assets
us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss · last filed 2026-02-19
- 2025-12-31: Contract with Customer, Asset, Allowance for Credit Loss $79.36M.
- 2024-12-31: Contract with Customer, Asset, Allowance for Credit Loss $22.26M.
- 2023-12-31: Contract with Customer, Asset, Allowance for Credit Loss $25.66M.
- 2022-12-31: Contract with Customer, Asset, Allowance for Credit Loss $19.80M.
| Period end | Contract with Customer, Asset, Allowance for Credit Loss |
|---|---|
| 2025-12-31 | $79.36M 10-K · filed 2026-02-19 |
| 2024-12-31 | $22.26M 10-K · filed 2026-02-19 |
| 2023-12-31 | $25.66M 10-K · filed 2026-02-19 |
| 2022-12-31 | $19.80M 10-K · filed 2025-02-20 |
| 2021-12-31 | $8.40M 10-K · filed 2024-02-22 |
| 2020-12-31 | $4.97M 10-K · filed 2023-02-23 |
| 2019-12-31 | $5.63M 10-K · filed 2022-02-17 |
| 2018-12-31 | $922.00K 10-K · filed 2021-02-25 |
| 2017-12-31 | $0.00 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |